BCMA-Specific CAR-T Cells for Multiple Myeloma Relapse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma are ineffective in providing a cure, as nearly all patients eventually relapse due to resistance to existing therapies.
Innovation Solution
Development of chimeric antigen receptors (CARs) specific to B-Cell Maturation Antigen (BCMA) that can be expressed on immune cells, such as T cells, to target and eliminate BCMA-expressing malignant cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for multiple myeloma are used, then initial remission can be achieved, but patients eventually relapse due to therapy resistance
Solution Approach 1:
The patent applies parameter changes by modifying the therapeutic approach from conventional chemotherapy to CAR-T cell therapy with BCMA-specific chimeric antigen receptors. This fundamental parameter change in treatment modality enables sustained remission by targeting the specific antigen BCMA on myeloma cells, overcoming the relapse issue associated with traditional therapies.
Solution Approach 2:
The patent employs copying by creating genetically modified T cells that replicate and persist in the patient's body. These CAR-T cells serve as living copies of the immune system's defense mechanism, continuously seeking and eliminating BCMA-expressing myeloma cells, thereby providing long-lasting therapeutic effect rather than temporary remission.
2Reliability
If chimeric antigen receptors specific to BCMA are expressed on immune cells, then cytotoxic activity against malignant cells is enhanced, but the complexity of the treatment increases
Solution Approach 1:
The patent uses an intermediary approach by introducing a third component - the CAR-T cell therapy - that mediates between the patient's immune system and the malignant cells. The chimeric antigen receptors act as intermediaries that bridge T cell activation mechanisms with specific recognition of BCMA on myeloma cells, enabling targeted cytotoxic activity while managing treatment complexity through a standardized cellular product.
Data Source
Figure 1
Figure 2
AI summary
The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).